Metformin‐induced KLF2 activation may lead to a beneficial effect in the amelioration of cardiovascular disorders, according to preclinical studies, as it has been shown that metformin attenuates endotoxemia‐induced endothelial dysfunction and proinflammatory response via activation of the AMPK/KLF2 axis. This evidence concerns the gene KLF2 and serum lipopolysaccharide activity.